Thursday, December 15, 2016

BRIEF-Aptevo Therapeutics amends collaboration agreement with Morphosys AG for Novel Immunotherapeutic

* Under terms of third amendment, Aptevo Research and

Development will bear 75 pct of all development costs with

respect to MOR209/es414

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)